Which pregnancy category is assigned to Oseltamivir Phosphate?

Oseltamivir Phosphate, commonly known as Tamiflu, is classified under Pregnancy Category C. This category indicates that while animal reproduction studies have shown an adverse effect on the fetus, there are no adequate and well-controlled studies in pregnant women. The benefits of treatment may warrant use of the drug in pregnant women despite potential risks.

In this case, the classification reflects the balance of potential benefits against possible risks during pregnancy. This information is crucial for healthcare providers when considering treatment options for pregnant patients who are at risk for or are experiencing influenza.

The other categories—A, B, and D—are used to indicate varying degrees of risk based on available data. Category A indicates that controlled studies in pregnant women show no risk, Category B suggests no risk in animal studies with no adequate studies in humans, and Category D suggests positive evidence of risk. Therefore, Oseltamivir Phosphate is accurately placed in Category C due to the lack of significant studies providing clear evidence of its safety in human pregnancy.